Reuters logo
BRIEF-Mochida Pharmaceutical signs contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.
March 6, 2017 / 6:15 AM / in 9 months

BRIEF-Mochida Pharmaceutical signs contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.

March 6 (Reuters) - Mochida Pharmaceutical Co Ltd:

* Says it signed a contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.

Source text in Japanese: goo.gl/V48nlh

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below